300 related articles for article (PubMed ID: 30615179)
1. The effect of interactions between proteinuria, activity of fibroblast growth factor 23 and serum phosphate on renal progression in patients with chronic kidney disease: a result from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease study.
Kim H; Park J; Nam KH; Jhee JH; Yun HR; Park JT; Han SH; Chung W; Oh KH; Park SK; Kim SW; Kang SW; Choi KH; Ahn C; Yoo TH
Nephrol Dial Transplant; 2020 Mar; 35(3):438-446. PubMed ID: 30615179
[TBL] [Abstract][Full Text] [Related]
2. Mediation of the relationship between proteinuria and serum phosphate: Insight from the KNOW-CKD study.
Jung JY; Ro H; Chang JH; Kim AJ; Lee HH; Han SH; Yoo TH; Lee KB; Kim YH; Kim SW; Park SK; Chae DW; Oh KH; Ahn C; Chung W
PLoS One; 2020; 15(6):e0235077. PubMed ID: 32569271
[TBL] [Abstract][Full Text] [Related]
3. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
6. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
8. Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study.
Yamanouchi M; Furuichi K; Hoshino J; Toyama T; Hara A; Shimizu M; Kinowaki K; Fujii T; Ohashi K; Yuzawa Y; Kitamura H; Suzuki Y; Sato H; Uesugi N; Hisano S; Ueda Y; Nishi S; Yokoyama H; Nishino T; Samejima K; Kohagura K; Shibagaki Y; Mise K; Makino H; Matsuo S; Ubara Y; Wada T;
Diabetes Care; 2019 May; 42(5):891-902. PubMed ID: 30833372
[TBL] [Abstract][Full Text] [Related]
9. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
Sakan H; Nakatani K; Asai O; Imura A; Tanaka T; Yoshimoto S; Iwamoto N; Kurumatani N; Iwano M; Nabeshima Y; Konishi N; Saito Y
PLoS One; 2014; 9(1):e86301. PubMed ID: 24466013
[TBL] [Abstract][Full Text] [Related]
10. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
11. Changes in FGF-23, Neutrophil/Platelet Activation Markers, and Angiogenin in Advanced Chronic Kidney Disease and Their Effect on Arterial Stiffness.
Choi HM; Kwon YE; Kim S; Oh DJ
Kidney Blood Press Res; 2019; 44(5):1166-1178. PubMed ID: 31553973
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and renal function among young and healthy individuals.
Bernasconi R; Aeschbacher S; Blum S; Mongiat M; Girod M; Todd J; Estis J; Nolan N; Renz H; Risch L; Conen D; Risch M
Clin Chem Lab Med; 2018 Aug; 56(9):1483-1489. PubMed ID: 29708879
[TBL] [Abstract][Full Text] [Related]
14. Serum Calciprotein Monomers and Chronic Kidney Disease Progression.
Tiong MK; Holt SG; Ford ML; Smith ER
Am J Nephrol; 2022; 53(11-12):806-815. PubMed ID: 36473431
[TBL] [Abstract][Full Text] [Related]
15. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
[TBL] [Abstract][Full Text] [Related]
16. Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling.
de Seigneux S; Courbebaisse M; Rutkowski JM; Wilhelm-Bals A; Metzger M; Khodo SN; Hasler U; Chehade H; Dizin E; Daryadel A; Stengel B; ; Girardin E; Prié D; Wagner CA; Scherer PE; Martin PY; Houillier P; Feraille E
J Am Soc Nephrol; 2015 Jul; 26(7):1608-18. PubMed ID: 25349200
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
[TBL] [Abstract][Full Text] [Related]
18. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
19. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
Muras K; Masajtis-Zagajewska A; Nowicki M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
[TBL] [Abstract][Full Text] [Related]
20. Acid Load and Phosphorus Homeostasis in CKD.
Khairallah P; Isakova T; Asplin J; Hamm L; Dobre M; Rahman M; Sharma K; Leonard M; Miller E; Jaar B; Brecklin C; Yang W; Wang X; Feldman H; Wolf M; Scialla JJ;
Am J Kidney Dis; 2017 Oct; 70(4):541-550. PubMed ID: 28645705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
